CorMedix (CRMD) Projected to Post Quarterly Earnings on Tuesday

CorMedix (NASDAQ:CRMD) is anticipated to post its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect CorMedix to post earnings of $0.8160 per share and revenue of $127.0190 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:30 AM ET.

CorMedix (NASDAQ:CRMD) last released its quarterly earnings data on Thursday, March 5th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.86 by ($0.70). CorMedix had a return on equity of 52.30% and a net margin of 52.31%.The business had revenue of $128.62 million during the quarter, compared to the consensus estimate of $127.02 million. During the same period last year, the business posted $0.22 earnings per share. The firm’s quarterly revenue was up 312.1% on a year-over-year basis. On average, analysts expect CorMedix to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

CorMedix Stock Performance

Shares of CRMD stock opened at $6.71 on Monday. The company’s fifty day simple moving average is $7.09 and its two-hundred day simple moving average is $9.55. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.11 and a quick ratio of 1.94. CorMedix has a 1 year low of $5.60 and a 1 year high of $17.43. The stock has a market capitalization of $530.43 million, a price-to-earnings ratio of 3.36 and a beta of 1.31.

CorMedix announced that its Board of Directors has initiated a share repurchase program on Monday, February 2nd that authorizes the company to buyback $75.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 12.3% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CRMD. Truist Financial set a $16.00 target price on CorMedix in a report on Thursday, January 8th. D. Boral Capital reissued a “buy” rating and issued a $14.00 price target on shares of CorMedix in a report on Wednesday, February 11th. Zacks Research lowered shares of CorMedix from a “hold” rating to a “strong sell” rating in a research report on Tuesday, February 10th. Needham & Company LLC reduced their price objective on shares of CorMedix from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of CorMedix in a report on Wednesday, January 21st. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, CorMedix has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Insider Buying and Selling

In related news, Director Alan W. Dunton sold 20,000 shares of the business’s stock in a transaction dated Tuesday, December 30th. The stock was sold at an average price of $13.00, for a total transaction of $260,000.00. Following the completion of the transaction, the director directly owned 40,250 shares in the company, valued at $523,250. The trade was a 33.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.10% of the stock is currently owned by insiders.

Institutional Trading of CorMedix

A number of large investors have recently modified their holdings of CRMD. Comerica Bank increased its position in shares of CorMedix by 454.6% in the third quarter. Comerica Bank now owns 2,690 shares of the company’s stock worth $31,000 after purchasing an additional 2,205 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in CorMedix during the second quarter valued at approximately $42,000. Kestra Advisory Services LLC bought a new stake in CorMedix during the fourth quarter valued at approximately $49,000. Caitong International Asset Management Co. Ltd grew its stake in CorMedix by 666.6% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 4,385 shares of the company’s stock worth $51,000 after buying an additional 3,813 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. purchased a new position in CorMedix in the 3rd quarter worth approximately $55,000. Institutional investors own 34.18% of the company’s stock.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.